A
Atossa Therapeutics, Inc. (ATOS)
NCM – Real vaqt narxi. Valyuta: USD
4.72
+0.01 (0.21%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
4.95
+0.23 (4.87%)
Bozordan keyin: Mar 27, 2026, 7:51 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NCM – Real vaqt narxi. Valyuta: USD
4.72
+0.01 (0.21%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
4.95
+0.23 (4.87%)
Bozordan keyin: Mar 27, 2026, 7:51 PM EDT
Atossa Therapeutics, Inc. klinik bosqichdagi biofarmatsevtika kompaniyasi sifatida faoliyat yuritadi, u AQShda onkologiyada ayollar ko'krak bezi saratoni va boshqa kasalliklar uchun qondirilmagan tibbiy ehtiyojlar sohalarida dori vositalarini ishlab chiqadi. Kompaniyaning asosiy dori nomzodi og'iz orqali qabul qilinadigan (Z)-endoxifendir, tamoksifenning faol metaboliti, u ko'krak bezi saratonini davolash va oldini olish uchun II bosqich klinik sinovlarida. Kompaniya immunoterapiya/ximerik antigen retseptor terapiyasi dasturlarini ham ishlab chiqadi. Kompaniya ilgari Atossa Genetics Inc. nomi bilan tanilgan va 2020 yil yanvar oyida Atossa Therapeutics, Inc. nomini o'zgartirgan. Atossa Therapeutics, Inc. 2008 yilda tashkil etilgan va Vashingtonning Sietl shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer |
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, CEO & President |
| Mr. Mark Daniel CPA | Chief Financial Officer |
| Ms. Delly Behen P.H.R. | Senior Vice President of Business Operations |
| Ms. Janet Rose Rea MSPH, RAC | Senior Vice President of Research & Development |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-20 | PRE 14A | atos-20260320.htm |
| 2026-01-26 | 8-K | atos-20260120.htm |
| 2026-01-09 | 8-K | atos-20260109.htm |
| 2026-01-06 | 8-K | atos-20260106.htm |
| 2025-12-22 | DEF 14A | atos-20251219.htm |
| 2025-12-12 | PRE 14A | atos-20251212.htm |
| 2025-12-04 | 8-K | atos-20251204.htm |
| 2025-11-12 | 8-K | atos-20251112.htm |
| 2025-10-14 | 8-K | atos-20251014.htm |
| 2025-09-26 | 8-K | atos-20250926.htm |